ARCHIVES

Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

AACR Meeting: Celebrex Studies Show Benign Polyp Reduction, Point To Challenges In Biomarker Validation.

April 14, 2006

Senate confirms Crawford as FDA commissioner.

July 22, 2005

Report Tells NCI to Increase Funding for SPOREs.

June 30, 2006

NCI CTEP-Approved Trials For the Month of March

March 28, 2014

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

NCI Grant Funding: “Zone of Likelihood” Moves From 7th to 9th Percentile

November 30, 2012